Kaneda Y - Search Results

1

New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.

Kawano H, Komaba S, Yamasaki T, Maeda M, Kimura Y, Maeda A, Kaneda Y. Kawano H, et al. Among authors: kaneda y. Cancer Chemother Pharmacol. 2008 May;61(6):973-8. doi: 10.1007/s00280-007-0553-1. Epub 2007 Jul 26. Cancer Chemother Pharmacol. 2008. PMID: 17653716

2

Development of HVJ envelope vector and its application to gene therapy.

Kaneda Y, Yamamoto S, Nakajima T. Kaneda Y, et al. Adv Genet. 2005;53:307-32. Adv Genet. 2005. PMID: 16240999 Review.

3

Development of high-throughput functional screening of therapeutic genes, using a hemagglutinating virus of Japan envelope vector.

Nishikawa T, Nakagami H, Matsuki A, Maeda A, Yo CY, Harada T, Morishita R, Tamai K, Kaneda Y. Nishikawa T, et al. Among authors: kaneda y. Hum Gene Ther. 2006 Apr;17(4):470-5. doi: 10.1089/hum.2006.17.470. Hum Gene Ther. 2006. PMID: 16610935

4

Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector.

Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, Kaneda Y. Mima H, et al. Among authors: kaneda y. Mol Cancer Ther. 2006 Apr;5(4):1021-8. doi: 10.1158/1535-7163.MCT-05-0352. Mol Cancer Ther. 2006. PMID: 16648574

5

A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.

Kawano H, Komaba S, Kanamori T, Kaneda Y. Kawano H, et al. Among authors: kaneda y. BMC Med. 2007 Sep 21;5:28. doi: 10.1186/1741-7015-5-28. BMC Med. 2007. PMID: 17883878 Free PMC article.

6

Development of a novel antimicrobial peptide, AG-30, with angiogenic properties.

Nishikawa T, Nakagami H, Maeda A, Morishita R, Miyazaki N, Ogawa T, Tabata Y, Kikuchi Y, Hayashi H, Tatsu Y, Yumoto N, Tamai K, Tomono K, Kaneda Y. Nishikawa T, et al. Among authors: kaneda y. J Cell Mol Med. 2009 Mar;13(3):535-46. doi: 10.1111/j.1582-4934.2008.00341.x. Epub 2008 Apr 9. J Cell Mol Med. 2009. PMID: 18410525 Free PMC article.

7

Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle.

Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Kawaguchi Y, et al. Among authors: kaneda y. Int J Cancer. 2009 May 15;124(10):2478-87. doi: 10.1002/ijc.24234. Int J Cancer. 2009. PMID: 19173282

8

Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon.

Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y. Tanaka M, et al. Among authors: kaneda y. Int J Cancer. 2010 Apr 15;126(8):1982-1991. doi: 10.1002/ijc.24965. Int J Cancer. 2010. PMID: 19830690

9

Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo.

Fujii H, Matsuyama A, Komoda H, Sasai M, Suzuki M, Asano T, Doki Y, Kirihata M, Ono K, Tabata Y, Kaneda Y, Sawa Y, Lee CM. Fujii H, et al. Among authors: kaneda y. Radiat Oncol. 2011 Jan 20;6:8. doi: 10.1186/1748-717X-6-8. Radiat Oncol. 2011. PMID: 21247507 Free PMC article.

10

Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents.

Nakagami H, Nishikawa T, Tamura N, Maeda A, Hibino H, Mochizuki M, Shimosato T, Moriya T, Morishita R, Tamai K, Tomono K, Kaneda Y. Nakagami H, et al. Among authors: kaneda y. J Cell Mol Med. 2012 Jul;16(7):1629-39. doi: 10.1111/j.1582-4934.2011.01406.x. J Cell Mol Med. 2012. PMID: 21812915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,103 results

Search Page

Filters